While the medicinal benefits of cannabidiol (CBD) are becoming increasingly understood, researchers have found its bioavailability is fairly low.
This has prompted scientists to investigate ways to improve the molecule’s efficacy. By changing its formulation or in some cases, developing a similar compound.
Neuropathix synthesised their proprietary molecule, KLS-13019. In a scientific study, the researchers compared the compound CBD and KLS-13019. They found that their compound had a bioavailability of 67 percent versus CBD’s eight percent.
Playing god comes to mind when humans start changing things at a molecular level. But these scientists believe they can in a way re-make the CBD compound so that it would have more bioavailability.
What does that mean?
In laymen’s terms bioavailability is the amount of a drug that reaches the blood regardless of how it is given.
Basically when we ingest something part of it will end up in our blood, but not all of it. These scientists believe they can increase that amount of CBD that stays in the bloodstream by playing with a certain molecule.
How does that help?
Furthermore, the potential for liver toxicity would be reduced with the CBD-inspired molecule.
This was due to the formulation of the molecule, which was more water-soluble, potentially allowing better clearance of the product in the liver.
The researchers behind KLS-13019 have also developed several backup compounds that could be potential leads if KLS-13019 fails at any stage. These can all be scaled up both in-house and through third parties as it ensures their supply should they need to focus on any of the other compounds.
CBD has come a very long way since its discovery and this is just the beginning. As there are still around 300 other compounds within cannabis that we are yet to study as much as we have done with CBD.
